Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT07169734) titled 'A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Alentis Therapeutics AG
Condition:
Cervical Squamous Cell Carcinoma
Squamous Non-small-cell Lung Cancer
Colorectal Cancer
Intrahepatic Cholangiocarcinoma
Urothelial Carcinoma
Intervention:
Drug: ALE.P03
Drug: ALE.P03
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollm...